407 related articles for article (PubMed ID: 20811720)
21. Functional interplay between MYCN, NCYM, and OCT4 promotes aggressiveness of human neuroblastomas.
Kaneko Y; Suenaga Y; Islam SM; Matsumoto D; Nakamura Y; Ohira M; Yokoi S; Nakagawara A
Cancer Sci; 2015 Jul; 106(7):840-7. PubMed ID: 25880909
[TBL] [Abstract][Full Text] [Related]
22. High level MycN expression in non-MYCN amplified neuroblastoma is induced by the combination treatment nutlin-3 and doxorubicin and enhances chemosensitivity.
Peirce SK; Findley HW
Oncol Rep; 2009 Dec; 22(6):1443-9. PubMed ID: 19885598
[TBL] [Abstract][Full Text] [Related]
23. Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells.
Molenaar JJ; Ebus ME; Geerts D; Koster J; Lamers F; Valentijn LJ; Westerhout EM; Versteeg R; Caron HN
Proc Natl Acad Sci U S A; 2009 Aug; 106(31):12968-73. PubMed ID: 19525400
[TBL] [Abstract][Full Text] [Related]
24. Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells.
Wallick CJ; Gamper I; Thorne M; Feith DJ; Takasaki KY; Wilson SM; Seki JA; Pegg AE; Byus CV; Bachmann AS
Oncogene; 2005 Aug; 24(36):5606-18. PubMed ID: 16007177
[TBL] [Abstract][Full Text] [Related]
25. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas.
Huang R; Cheung NK; Vider J; Cheung IY; Gerald WL; Tickoo SK; Holland EC; Blasberg RG
FASEB J; 2011 Dec; 25(12):4138-49. PubMed ID: 21856782
[TBL] [Abstract][Full Text] [Related]
26. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
[TBL] [Abstract][Full Text] [Related]
27. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells.
Kang JH; Rychahou PG; Ishola TA; Qiao J; Evers BM; Chung DH
Biochem Biophys Res Commun; 2006 Dec; 351(1):192-7. PubMed ID: 17055458
[TBL] [Abstract][Full Text] [Related]
28. p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas.
Dreidax D; Bannert S; Henrich KO; Schröder C; Bender S; Oakes CC; Lindner S; Schulte JH; Duffy D; Schwarzl T; Saadati M; Ehemann V; Benner A; Pfister S; Fischer M; Westermann F
Hum Mol Genet; 2014 Dec; 23(25):6826-37. PubMed ID: 25104850
[TBL] [Abstract][Full Text] [Related]
29. Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells.
Condorelli F; Gnemmi I; Vallario A; Genazzani AA; Canonico PL
Br J Pharmacol; 2008 Feb; 153(4):657-68. PubMed ID: 18059320
[TBL] [Abstract][Full Text] [Related]
30. Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line.
Chevrier L; Meunier AC; Cochaud S; Muller JM; Chadéneau C
Int J Oncol; 2008 Nov; 33(5):1081-9. PubMed ID: 18949372
[TBL] [Abstract][Full Text] [Related]
31. Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma.
Dolman ME; Poon E; Ebus ME; den Hartog IJ; van Noesel CJ; Jamin Y; Hallsworth A; Robinson SP; Petrie K; Sparidans RW; Kok RJ; Versteeg R; Caron HN; Chesler L; Molenaar JJ
Clin Cancer Res; 2015 Nov; 21(22):5100-9. PubMed ID: 26202950
[TBL] [Abstract][Full Text] [Related]
32. A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF.
Iraci N; Diolaiti D; Papa A; Porro A; Valli E; Gherardi S; Herold S; Eilers M; Bernardoni R; Della Valle G; Perini G
Cancer Res; 2011 Jan; 71(2):404-12. PubMed ID: 21123453
[TBL] [Abstract][Full Text] [Related]
33. GSK3 inhibitors regulate MYCN mRNA levels and reduce neuroblastoma cell viability through multiple mechanisms, including p53 and Wnt signaling.
Duffy DJ; Krstic A; Schwarzl T; Higgins DG; Kolch W
Mol Cancer Ther; 2014 Feb; 13(2):454-67. PubMed ID: 24282277
[TBL] [Abstract][Full Text] [Related]
34. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM
Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562
[TBL] [Abstract][Full Text] [Related]
35. Novel anthranilamide-pyrazolo[1,5-a]pyrimidine conjugates modulate the expression of p53-MYCN associated micro RNAs in neuroblastoma cells and cause cell cycle arrest and apoptosis.
Ramaiah MJ; Pushpavalli SN; Lavanya A; Bhadra K; Haritha V; Patel N; Tamboli JR; Kamal A; Bhadra U; Pal-Bhadra M
Bioorg Med Chem Lett; 2013 Oct; 23(20):5699-706. PubMed ID: 23992861
[TBL] [Abstract][Full Text] [Related]
36. Oncolytic adenovirus-mediated short hairpin RNA targeting MYCN gene induces apoptosis by upregulating RKIP in neuroblastoma.
Li Y; Zhang H; Zhu X; Feng D; Zhang D; Zhuo B; Zheng J
Tumour Biol; 2015 Aug; 36(8):6037-43. PubMed ID: 25736927
[TBL] [Abstract][Full Text] [Related]
37. Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.
Chen Z; Lin Y; Barbieri E; Burlingame S; Hicks J; Ludwig A; Shohet JM
Neoplasia; 2009 Aug; 11(8):753-62. PubMed ID: 19649205
[TBL] [Abstract][Full Text] [Related]
38. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B
Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764
[TBL] [Abstract][Full Text] [Related]
39. MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.
Zhang S; Wei JS; Li SQ; Badgett TC; Song YK; Agarwal S; Coarfa C; Tolman C; Hurd L; Liao H; He J; Wen X; Liu Z; Thiele CJ; Westermann F; Asgharzadeh S; Seeger RC; Maris JM; Guidry Auvil JM; Smith MA; Kolaczyk ED; Shohet J; Khan J
Cancer Lett; 2016 Feb; 371(2):214-24. PubMed ID: 26683771
[TBL] [Abstract][Full Text] [Related]
40. Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma.
Muth D; Ghazaryan S; Eckerle I; Beckett E; Pöhler C; Batzler J; Beisel C; Gogolin S; Fischer M; Henrich KO; Ehemann V; Gillespie P; Schwab M; Westermann F
Cancer Res; 2010 May; 70(9):3791-802. PubMed ID: 20424123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]